Keros Therapeutics Inc
kerostx.comKeros Therapeutics Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company developing treatments targeting the TGF-beta protein superfamily pathway. The company generates no product revenue, funding operations through equity financing while advancing its pipeline of drug candidates. As of the 10-K filed 2026-03-04, Keros had committed approximately $1.6 million under contract manufacturing agreements expected to be paid through 2029. Its lead product candidates include rinvatercept and elritercept, both in clinical development. The company has an accumulated deficit reflected on its December 31, 2025 balance sheet and relies on external capital to fund research and development activities. Keros is incorporated in Delaware and headquartered in the United States. No product revenue, partnership revenue, or licensing revenue figures were disclosed in the available filing excerpts.
Products & Services
Pipeline drug candidates rinvatercept and elritercept, both in clinical development as of the 10-K filed 2026-03-04. No approved or commercialized products disclosed in the filing excerpts.
Revenue Model
Pre-revenue clinical-stage company. No product sales or disclosed licensing or collaboration revenue as of the 10-K filed 2026-03-04. Operations funded through equity capital markets.
Customers & Markets
No commercial customers as of the 10-K filed 2026-03-04. End markets, if products reach approval, would include patients and payers in the U.S. healthcare system, subject to ACA and Medicaid reimbursement frameworks.
Geographic Exposure
Primarily United States-based operations, with data privacy obligations extending to the European Economic Area and United Kingdom based on cross-border data transfer disclosures in the 10-K filed 2026-03-04.
Financial Snapshot
Loading...
